Tuesday, July 9, 2024

CATEGORY

AbbVie

Ulcerative Colitis Treatment Advances with FDA Approval of AbbVie’s Skyrizi

Ulcerative colitis (UC) treatment has advanced with the Food and Drug Administration’s (FDA) approval of AbbVie’s Skyrizi (risankizumab-rzaa) for adults with moderately to severely...

Antibody-Drug Conjugates Data Across Multiple Indications Presented by AbbVie at ASCO 2024

Antibody-drug conjugates (ADCs) ABBV-400 and ABBV-706 were the focus of new data presented by AbbVie at this year's American Society of Clinical Oncology (ASCO)...

Arthritis Treatment Expanded: FDA Approves Upadacitinib for Pediatric Use

Arthritis treatment with upadacitinib (Rinvoq) by Abbvie has been approved by the U.S. Food and Drug Administration (FDA) for pediatric patients with juvenile idiopathic...

Revolutionizing Migraine Treatment: NICE Endorses Aquipta, Expanding Accessibility and Care Options within the NHS

AbbVie's Aquipta has received a significant endorsement from the National Institute for Health and Care Excellence (NICE), marking a pivotal milestone in migraine treatment...

A New Horizon for Ovarian Cancer Treatment: Elahere Wins Full FDA Approval

Elahere represents a groundbreaking advancement in the field of oncology, specifically targeting ovarian cancer—a condition notoriously difficult to treat due to its resistance to...

FDA Approves Allergan’s Temple Hollowing Treatment Juvéderm, a First in HA Dermal Fillers

Allergan Aesthetics, a subsidiary of AbbVie, has received FDA approval for Juvéderm Voluma XC to address moderate to severe temple hollowing in adults aged...

FDA Approves Leukemia and Lymphoma Treatment Imbruvica’s New Oral Suspension Form

The FDA has expanded the label for Imbruvica (ibrutinib) to include an oral suspension formulation, extending its usage to various indications like leukemia, lymphoma,...

FDA Grants Priority Review to Follicular Lymphoma Treatment Epkinly by Genmab and AbbVie’s

The U.S. Food and Drug Administration (FDA) has bestowed Priority Review status upon a supplemental Biologics License Application (sBLA) submitted by Genmab A/S and...

Simlandi’s Approval Revolutionizes Biosimilar Landscape: A Game-Changer for Humira’s Dominance

Pharmacists in the United States are now granted the authority to substitute a more affordable biosimilar version for AbbVie's high-concentration formulation of Humira without...

AbbVie’s Tepkinly for Lymphoma Patients Approved by NICE

The National Institute for Health and Care Excellence (NICE) has given its approval for the use of AbbVie's CD20xCD3 bispecific antibody, Tepkinly (epcoritamab), within...

Latest news